Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice.
The activity of roxithromycin against three clinical isolates of Mycobacterium avium was compared with that of clarithromycin both in a model of infection of human monocyte-derived macrophages and in a model of established infection of C57BL/6 mice. In the cell culture model, roxithromycin and clarithromycin were bactericidal for strains MO-1 and N-92159 and bacteriostatic for strain N-93043. For the three strains, the differences between the intracellular activities of roxithromycin and clarithromycin were not singificant after 7 days of treatment. Mice were infected with the MO-1 strain. Drugs were given by gavage at a dosage of 200 mg/kg of body weight 6 days per week for 16 weeks starting 5 weeks after infection. At the end of treatment, clarithromycin was more effective than roxithromycin in lungs; roxithromycin was as effective as clarithromycin in spleens. Thus, the activity of roxithromycin was comparable to that of clarithromycin both in vitro and in vivo.
Struillou
L
L
Institut National de la Santé et de la Recherche Médicale Unité 13, Hôpital Bichat-Claude Bernard, Paris, France.
Cohen
Y
Y
Lounis
N
N
Bertrand
G
G
Grosset
J
J
Vildé
J L
JL
Pocidalo
J J
JJ
Perronne
C
C
D000818:Animals; D017291:Clarithromycin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008264:Macrophages / Q000382:microbiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009162:Mycobacterium avium / Q000187:drug effects*; D015575:Roxithromycin / Q000494:pharmacology* / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*
D015575:Roxithromycin; D017291:Clarithromycin